PMID- 21264211
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20211020
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 6
IP  - 1
DP  - 2011 Jan 17
TI  - Identification of chronic heart failure patients with a high 12-month mortality 
      risk using biomarkers including plasma C-terminal pro-endothelin-1.
PG  - e14506
LID - 10.1371/journal.pone.0014506 [doi]
LID - e14506
AB  - OBJECTIVES: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 
      (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in 
      patients with chronic heart failure (CHF), beyond other prognosticators, 
      including N-terminal pro-B-type natriuretic peptide (NT-proBNP). METHODS: We 
      examined 491 patients with systolic CHF (age: 63+/-11 years, 91% men, New York 
      Heart Association [NYHA] class [I/II/III/IV]: 9%/45%/38%/8%, 69% ischemic 
      etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. 
      RESULTS: Increasing CT-proET-1 was a predictor of increased cardiovascular 
      mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% 
      confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left 
      ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver 
      operating characteristic curve analysis, areas under curve for 12-month follow-up 
      were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and 
      CT-proET-1 added prognostic value to a base model that included LVEF, age, 
      creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger 
      prognostic power (p<0.01) than adding NT-proBNP (p<0.01). Adding CT-proET-1 to 
      NT-proBNP in this model yielded further prognostic information (p = 0.02). 
      CONCLUSIONS: Plasma CT-proET-1 constitutes a novel predictor of increased 
      12-month cardiovascular mortality in patients with CHF. High CT-proET-1 together 
      with high NT-proBNP enable to identify patients with CHF and particularly 
      unfavourable outcomes.
FAU - Jankowska, Ewa A
AU  - Jankowska EA
AD  - Department of Heart Diseases, Wroclaw Military Hospital, Wroclaw, Poland. 
      Ewa.Jankowska@antro.pan.wroc.pl
FAU - Filippatos, Gerasimos S
AU  - Filippatos GS
FAU - von Haehling, Stephan
AU  - von Haehling S
FAU - Papassotiriou, Jana
AU  - Papassotiriou J
FAU - Morgenthaler, Nils G
AU  - Morgenthaler NG
FAU - Cicoira, Mariantonietta
AU  - Cicoira M
FAU - Schefold, Joerg C
AU  - Schefold JC
FAU - Rozentryt, Piotr
AU  - Rozentryt P
FAU - Ponikowska, Beata
AU  - Ponikowska B
FAU - Doehner, Wolfram
AU  - Doehner W
FAU - Banasiak, Waldemar
AU  - Banasiak W
FAU - Hartmann, Oliver
AU  - Hartmann O
FAU - Struck, Joachim
AU  - Struck J
FAU - Bergmann, Andreas
AU  - Bergmann A
FAU - Anker, Stefan D
AU  - Anker SD
FAU - Ponikowski, Piotr
AU  - Ponikowski P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110117
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Endothelin-1)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Precursors)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 0 (proendothelin 1)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Chronic Disease
MH  - Endothelin-1/*blood
MH  - Female
MH  - Heart Failure/diagnosis/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mortality
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Prognosis
MH  - Protein Precursors/*blood
MH  - Risk
PMC - PMC3022013
COIS- Competing Interests: Stephan von Haehling has received speaker's fees from 
      B.R.A.H.M.S. AG for giving presentations on biomarkers produced and marketed by 
      B.R.A.H.M.S. AG. Nils G. Morgenthaler, Jana Papassotiriou, Joachim Struck, Oliver 
      Hartmann, and Andreas Bergmann are employed by B.R.A.H.M.S. AG, which is a 
      biotech company that developed the CT-proET-1 assay. The funder B.R.A.H.M.S. AG 
      was involved in data collection and analysis and reviewed the manuscript before 
      submission. Andreas Bergmann is a member of the board of directors and 
      shareholder of B.R.A.H.M.S. AG. Stefan D. Anker has received consultant honoraria 
      from B.R.A.H.M.S. AG. This does not alter the authors' adherence to all the PLoS 
      ONE policies on sharing data and materials. All other authors report no conflict 
      of interest.
EDAT- 2011/01/26 06:00
MHDA- 2011/08/04 06:00
PMCR- 2011/01/17
CRDT- 2011/01/26 06:00
PHST- 2010/07/19 00:00 [received]
PHST- 2010/12/15 00:00 [accepted]
PHST- 2011/01/26 06:00 [entrez]
PHST- 2011/01/26 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
PHST- 2011/01/17 00:00 [pmc-release]
AID - 10-PONE-RA-21311R2 [pii]
AID - 10.1371/journal.pone.0014506 [doi]
PST - epublish
SO  - PLoS One. 2011 Jan 17;6(1):e14506. doi: 10.1371/journal.pone.0014506.